sparfloxacin has been researched along with Inflammation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, Y; Fan, B; Mao, Z; Wang, W; Wang, Y; Wu, J; Yang, Y | 1 |
| Andrews, JM; Cooper, MA; Johnson, JH; Wise, R | 1 |
2 other study(ies) available for sparfloxacin and Inflammation
| Article | Year |
|---|---|
Inflammation-targeting polymeric nanoparticles deliver sparfloxacin and tacrolimus for combating acute lung sepsis.
Topics: Animals; Anti-Bacterial Agents; Drug Carriers; Endothelial Cells; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Immunosuppressive Agents; Inflammation; Lactic Acid; Lung; Mice; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sepsis; Tacrolimus | 2020 |
Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.
Topics: Administration, Oral; Adult; Blister; Exudates and Transudates; Fluoroquinolones; Humans; Inflammation; Intestinal Absorption; Male; Quinolones | 1992 |